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The National Institute ofEnvironmental Health Sciences is supporting a multiyear research ini-
tiative examining geneticinfluences onenvironmental response. Proponents ofthis newinitiative,
known as the Environmental Genome Project, hope that the information learned will improve
our understanding ofenviromnentaly associated diseases and allow dinicians and public health
officials to target disease-prevention strategies to those who are at increased risk. Despite these
potential benefits, theprojectpresents several ethical and social challenges. Ofimmediate concern
is the protection ofindividual research participants. Other ethical issues relate to the application
ofresearch results and howstudyfindings couldaffect social priorities. Clarifyingtheseemerging
areas ofconcern, manyofwhich havenot received adequate attention in the existing bioethics lit-
erature, is an important step toward minimizing potential research-related risks and defining
research needs. Key words: Envirconmental Genome Project, environmental genomics, ethics,
genetic susceptibility, human subjects research, informed consent. Environ Health Perspect
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The National Institute of Environmental
Health Sciences recently launched a
new research initiative known as the
Environmental Genome Project (EGP)
(1-3). The EGP will examine how genetic
variation affects response to environmental
exposures. Initially, the project will identify
polymorphic variation in genes that appear
to play an important role in environmental-
ly associated diseases. Having identified
these genetic polymorphisms, researchers
then will examine their functional implica-
tions more carefully (4). These functional
studies will be multidisciplinary in approach,
incorporating research methodologies from
biochemistry, epidemiology, genetics, phar-
macology, and toxicology (5).
Proponents of the EGP hope that the
information learned will be instrumental in
improving public health (6). A better under-
standing of genetic influences on environ-
mental response could lead to more accurate
estimates ofdisease risks and provide a basis
for disease prevention and early intervention
programs directed at individuals and popula-
tions at increased risk (7). Identifying func-
tionally significant polymorphisms also
could shed light on disease pathways and
suggest targets for therapeutic intervention
(8,9).
Aswith all research, these potential bene-
fits must be weighed against possible risks.
Following the precedent developed in con-
nection with the Human Genome Project
(10,11), there are plans to support research
on the ethical, legal, and social implications
ofthe EGP (12). By examining these issues,
we may be able to anticipate problems
before they arise and develop policies that
maximize the benefits of the EGP while
minimizing its risks (13).
In this paper we highlight several ethical,
legal, and social issues raised by the EGP.
These issues are presented in the order that
they likely will present themselves to
researchers, beginning with the protection of
research participants and concluding with
potential long-term implications ofenviron-
mental genomic research. Our goal in pro-
viding this overview is to draw attention to
future research needs and encourage others
to join us in thinking about these difficult
and complex issues.
Current Issues: Protecting
Research Participants
The most immediate ethical, legal, and social
issues raised by the EGP relate to the protec-
tion of individual research participants
(14-16). Genetic studies often present special
challenges in protecting human subjects
because genetic research frequently poses psy-
chosocial risks that may be difficult to antici-
pate and convey to prospective participants
(17). These risks can indude possible discrim-
ination or stigmatization, disrupted relation-
ships between family members, and adverse
effects on aparticipant's self-image (18).
The presentation ofresearch-related risks
to participants is especially troublesome in
connection with the EGP because of the
many uncertainties surrounding the study of
genetic hypersensitivities to environmental
exposures. Studies of gene-environment
interactions often do not allow for precise
quantification of the respective genetic and
environmental contributions to disease (19).
As a result, research findings may be difficult
for researchers and participants to interpret.
A study may identify a genetic polymor-
phism that appears to play a role in environ-
mental response, but the extent to which its
effects are mediated by environmental fac-
tors often will remain unclear. Without
more information on an individual's genome
and past environmental exposures, the detec-
tion ofsuch a polymorphism is ofuncertain
value in predicting future disease. These
uncertainties complicate the process of
informed consent, particularly the commu-
nication of potential risks and benefits to
prospective participants (20). The inability
to quantify the precise extent to which a par-
ticular polymorphism increases disease risks
also makes it difficult to determine whether
research results should be disclosed to partic-
ipants, and ifso, in what manner (21).
Ifstudy results are conveyed to partici-
pants, still other complications present them-
selves (22). In many genetic studies, specially
trained genetic counselors discuss findings
with participants. This approach helps mini-
mize potential psychosocial risks. Although
genetic counselors could be used to convey
results obtained in connection with the EGP,
the current shortage of these professionals
likelywould make this apractical impossibili-
ty. Moreover, ifmanylaypersons overestimate
the predictive value of genetic information
(23), it maybe difficult to present findings on
genetic hypersensitivities to environmental
exposures in a manner that avoids placing too
much emphasis on genetic contributions to
disease. It is more likely that information on
increased susceptibility to environmentally
associated diseases will be viewed fatalistically,
prompting some to infer that because they
have agenetic predisposition to adisease, they
will eventually develop that condition. Such
misunderstandings are a concern in present-
ing study results to individual participants, as
well as in presenting research findings more
generally.
Other immediate ethical, legal, and
social issues relate to the breadth ofthe con-
sent obtained in connection with EGP stud-
ies (24). Associations between individual
alleles and particular environmental expo-
sures are difficult to identify. As a result,
researchers are interested in designing studies
that look at possible associations between
many different allelic variants and many
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different exposures concurrently. Although
such studies increase the likelihood ofidenti-
fying functionally significant polymorphisms,
they complicate the consent process. As more
genes and exposures are considered simulta-
neously, it becomes increasingly difficult to
anticipate the potential risks and benefits of
the research (25,26). Hence, it also becomes
more difficult to ensure that individual par-
ticipants are fully informed about the possi-
ble risks and benefits of their participation.
At the extreme, the worry is that individual
consent becomes a blanket permission for
genetic research in general (27). These broad
permissions are considered morally problem-
atic because it is unclear how participants
could be fully informed about such a wide
range ofpotential research uses (28).
A related concern is that current policies
governing informed consent could place
inappropriate restrictions on research in
environmental genomics (29). Although the
present standards for informed consent in
genetic research may be appropriate for stud-
ies of highly predictive alleles, they may be
overly demanding for studies of genetic
hypersensitivities to environmental expo-
sures, particularly because such studies gener-
ally present more limited risks to individual
participants. Thus the challenge facing the
EGP is to establish consent procedures that
allow individuals to make genuinely
informed choices about their participation in
studies that examine many different alleles
and multiple exposures concurrently. The
permissions granted by participants should
be broad enough to permit diverse research
interests, yet specific enough to allow indi-
vidual participants to assess the possible risks
and benefits oftheir participation.
Emerging Issues: Protecting
Socially Identifiable Groups
Many of the ethical, legal, and social issues
surrounding the EGP are familiar to experi-
enced researchers and Institutional Review
Boards. Although the EGP complicates these
familiar areas of concern, studies of genetic
influences on environmental response also
introduce other less familiar ethical and
social considerations. These concerns will
become more prominent as research in envi-
ronmental genomics expands and informa-
tion on common genetic hypersensitivities
becomes more widely available.
One such issue is the protection ofsocial-
ly identifiable groups, including racial and
ethnic populations. Some allelic variants are
more common in certain populations and
less common in others. As specific genetic
polymorphisms are associated with increased
susceptibility to environmental exposures, it
is likely that some genetic hypersensitivities
will be associated with particular social
groups (30). The association of genetic
hypersensitivities with race or ethnicity could
threaten the employment and insurance
opportunities available to entire groups of
individuals, notjust thosewho choose to par-
ticipate in research (31,32). Members of
these populations also could encounter
broader forms ofdiscrimination and stigma-
tization, for example, in child custody dis-
putes or adoption efforts (33,34). In this
regard, the association ofAshkenazi Jews
with BRCA1 mutations (and increased risk of
breast cancer) is suggestive ofthe type ofrisks
presented by studies ofgenetic influences on
environmental response (35,36).
In response to these research-related
risks, some have proposed that members of
study populations be involved directly in the
review of proposed research (37,38).
Involving community representatives early
in the design of research protocols could
help identify potential risks that otherwise
could go unnoticed (39). This approach has
been controversial and the effectiveness of
these supplemental protections has been
questioned (40,41). Additional discussion
and empirical research are needed to deter-
mine how best to incorporate the perspec-
tives of study populations in the review of
genetic research (42).
Long-Term Issues: Shifting
Social Priorities and
Responsibility for Health
Although it is difficult to speculate on the
long-term consequences of any area of
research, there are a number of broad social
considerations suggested by the EGP. One
such concern is that research on genetic
influences on environmental response could
affect how we view an individual's responsi-
bility for his or her overall health. It seems
reasonable to suggest that individuals with
known genetic hypersensitivities to particular
exposures are responsible for avoiding those
adverse exposures. Individuals who know
that they are particularly susceptible to the
toxins found in cigarette smoke, for example,
should quitsmoking. What is less clear, how-
ever, is howfarthis moral obligation extends.
For instance, suppose an individual has a
known hypersensitivity to an environmental
exposure that is very common and difficult to
avoid-exposure to low levels of direct sun-
light, for example. An individual may be able
to avoid such adverse exposures, but only by
taking extraordinary measures. Although pre-
ventive interventions are available, it is
unclear howwe should view those individuals
who fail to take such extraordinary measures
to lower their risk of disease. Insurers, for
example, may claim that individuals who do
not minimize their exposure to these agents
are responsible for any subsequent illness
because they knowingly placed themselves at
risk. Employers asked to pay for health costs
through workers' compensation may refuse
based on the idea that it was the individual
who knowingly took a job that placed him
or her at increased risk. In contrast, individ-
uals with heightened genetic sensitivities
may seek protection under the Americans
with Disabilities Act or state legislation pro-
tecting against genetic discrimination (43).
Currently, it is unclear how to resolve such
disputes or the extent to which information
on genetic hypersensitivities might be inap-
propriately used to avoid responsibility for ill-
ness. In part, these disputes concern possible
discriminatory uses of genetic information,
but the more fundamental issue is how infor-
mation on genetic risks will alter ourviews on
personal responsibility forone's health (12).
Other examples suggest further complica-
tions to the notion ofpersonal responsibility.
Suppose gene-modification techniques
become more effective than they are at pre-
sent. When certain genetic polymorphisms
help protect against adverse exposures, indi-
viduals maywish to alter theirgenetic makeup
to increase their tolerance to these exposures.
Given the scarcity ofmedical resources, such
applications ofgene-manipulation techniques
are unlikely to become commonplace.
However, because these genetic enhance-
ments could be purchased by wealthy indi-
viduals, their availability would contribute to
existing health disparities between the rich
and the poor. Genetically enhanced million-
aires could live recklessly, engaging in
unhealthy behaviors, whereas the poorwould
be held to a higher standard ofaccountability
for theirhealth.
Related to these considerations regarding
medical responsibility are concerns about the
effect the EGP and projects like it may have
on howwe viewat-risk, but currently asymp-
tomatic, individuals. As with other known
genetic susceptibilities to disease, some indi-
viduals who are at increased risk ofdevelop-
ing environmentally associated diseases will
view themselves, and will be viewed by
others, as ill-even though they may not be
exhibiting any symptoms of the disease and
may never develop the illness in question
(44). Ifassociations between particular poly-
morphisms and specific diseases prove diffi-
cult to quantify, the EGP could foster
such fatalistic attitudes by making it difficult
to specify the precise extent to which an
individual is at increased risk.
Other long-term considerations relate to
increased emphasis on the genetic causes of
disease. This trend, which has been described
as the geneticization of disease (45), could
foster the beliefthat social problems are pri-
marily the result of genetic causes. This
reduction of social problems to biological
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problems could change how we think about
social priorities. For example, employers may
be viewed as less responsible for improving
workplace conditions, with the focus of dis-
ease causation shifting from the hazardous
workplace to the predisposed worker.
Similarly, research funding may be diverted
away from preventive strategies for improving
public health, moving instead to approaches
stressing genetic influences on disease (46).
Areas for Future Research
It is expected that as the EGP develops, a
wide range ofethical, legal, and social issues
will emerge as important areas for additional
consideration. There is already extensive lit-
erature examining the social implications of
genetic research, much ofwhich is directly
relevant to the EGP. All too frequently,
however, policy recommendations focus on
rare alleles that are highly predictive of dis-
ease. It is unclear whether these moral and
legal perspectives are appropriate guides
when the alleles under investigation are
much more common and less predictive of
future disease (47,48).
In many ways, the EGP is representative
of a new type of genetic research program,
with its emphasis on the incorporation of
detailed genomic information into our under-
standing ofdisease susceptibility and individ-
ual response to environmental exposure.
Thus, it is not surprising that the social impli-
cations ofthe project have not been adequate-
lydiscussed in the existing bioethics literature.
As the field ofenvironmental genomics devel-
ops, researchers, legislators, and policy makers
will need to consider the extent to which tra-
ditional bioethical perspectives apply to this
new area of research. Thoughtful discussions
ofthe ethical, legal, and social implications of
environmental genomic research are critical to
the overall success of projects like the EGP.
We hope that this paper plays a role in foster-
ingthosediscussions.
For additional information on the ethi-
cal, legal and social implications ofthe EGP,
visit the project's web site (49).
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